Qiagen N.V. QGEN
49.89 USD -0.21 (-0.42%)
Regular-session close
49.69 -0.20 -0.40%
After hours · Nov 13, 4:01 PM ET
49.83 Day range 50.10
32.63 52-week range 55.66
- YTD
- +10.94%
- 1 year
- +11.74%
News
zacks.com Interpreting Qiagen (QGEN) International Revenue Trends Review Qiagen's (QGEN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
benzinga.com Qiagen Q3 Adj. EPS $0.65, Inline, Sales $548.000M Miss $573.331M Estimate Qiagen (NYSE:QGEN) reported quarterly earnings of $0.65 per share which met the analyst consensus estimate. This is a 12.07 percent increase over earnings of $0.58 per share from the same period last…
benzinga.com Barclays Downgrades Qiagen to Equal-Weight, Lowers Price Target to $53 Barclays analyst Luke Sergott downgrades Qiagen (NYSE:QGEN) from Overweight to Equal-Weight and lowers the price target from $55 to $53.
benzinga.com Citigroup Maintains Neutral on Qiagen, Raises Price Target to $52 Citigroup analyst Albert Hu maintains Qiagen (NYSE:QGEN) with a Neutral and raises the price target from $45 to $52.
benzinga.com Long-Awaited Qiagen Buyout Closes At 15x EBITDA Multiple as Slow Growth Curbs Pricing Qiagen agrees to a $12 billion all-cash buyout by EQT. Analysts view the valuation discount as warranted given slower growth.
benzinga.com This Qiagen Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday Analysts downgraded Qiagen, Alcoa and Dutch Bros, cutting price targets for Qiagen to $52 and Dutch Bros to $46.
benzinga.com JP Morgan Downgrades Qiagen to Neutral, Lowers Price Target to $52 JP Morgan analyst Casey Woodring downgrades Qiagen (NYSE:QGEN) from Overweight to Neutral and lowers the price target from $55 to $52.
benzinga.com Baird Maintains Outperform on Qiagen, Raises Price Target to $52 Baird analyst Catherine Schulte maintains Qiagen (NYSE:QGEN) with a Outperform and raises the price target from $50 to $52.
benzinga.com QIAGEN Reports Preliminary Q3 Net Sales Of $548M; Preliminary Q3 Adj EPS $0.65; Co. Suspends FY 2026 Outlook While Transaction With EQT Private Equity Is Pending QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced preliminary third-quarter 2026 financial results. Net sales were $548 million at both reported and constant exchange rates…- benzinga.com Qiagen And EQT Private Equity Agree On An All-Cash Public Takeover Offer For All Outstanding Qiagen Shares At An Offer Price Of €46.50 Per Share, A Premium Of 40.3% To The Unaffected Share Price; Closing Expected In Mid-2027 QIAGEN and EQT Private Equity agree on an all-cash public takeover offer for all outstanding QIAGEN shares at an offer price of €46.50 per share, a premium of 40.3% to the unaffected share…
- benzinga.com 'EQT Is in Advanced Talks to Buy Testing Firm Qiagen' - Bloomberg -Bloomberg.
benzinga.com Barclays Upgrades Qiagen to Overweight, Raises Price Target to $55 Barclays analyst Luke Sergott upgrades Qiagen (NYSE:QGEN) from Equal-Weight to Overweight and raises the price target from $40 to $55.
benzinga.com FDA Clears QIAGEN's Gram-Negative QIAstat-Dx Bloodstream Panel, Joining Gram-Positive And Fungal Panel To Cover 33 Pathogen Targets And 28 Resistance Marker Bloodstream infections can trigger sepsis, a life-threatening response to infection; about 1.7 million U.S. adults develop sepsis each year, contributing to at least 350,000 deathsNew QIAstat-Dx test…
benzinga.com Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit 10x Genomics won a $4.8 million patent infringement lawsuit against Qiagen subsidiary Parse Biosciences, prompting plans for an injunction.- benzinga.com 10x Genomics Wins Patent Case Against Parse Biosciences As Jury Finds Willful Infringement And Awards $4.8M+ In Damages; Company To Seek Enhanced Damages, Fees And Permanent Injunction Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challengePLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life…
- benzinga.com QIAGEN Appoints Jonathan M. Pratt CEO, Effective Sept. 1, Succeeding Thierry Bernard; Co. Reiterates Q3, FY26 Guidance QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than…
- benzinga.com QIAGEN Says FDA Clears QIAstat-Dx BCID GPF Plus AMR Panel For Bloodstream Infections QIAstat-Dx BCID GPF Plus AMR Panel detects 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in about one hourFDA clearance marks QIAGEN's entry into U.S.…
- benzinga.com Citigroup Maintains Neutral on Qiagen, Raises Price Target to $45 Citigroup analyst Brendan Digan maintains Qiagen (NYSE:QGEN) with a Neutral and raises the price target from $38 to $45.
- benzinga.com Barclays Maintains Equal-Weight on Qiagen, Raises Price Target to $40 Barclays analyst Luke Sergott maintains Qiagen (NYSE:QGEN) with a Equal-Weight and raises the price target from $38 to $40.
- benzinga.com JP Morgan Maintains Overweight on Qiagen, Raises Price Target to $50 JP Morgan analyst Casey Woodring maintains Qiagen (NYSE:QGEN) with a Overweight and raises the price target from $45 to $50.
- benzinga.com Conference Call:
Qiagen Q3 Adj EPS expected to be more than $0.62 vs $0.64 Est; Sees Q3 Sales $538.330M-$543.660M vs $552.590M Est Qiagen (NYSE:QGEN) Q3 expected to be more than $0.62 vs $0.64 Est. sees Q3 sales of $538.330 million-$543.660 million vs $552.590 million analyst estimate.
- benzinga.com Qiagen FY2026 Adj EPS expected to be more than $2.43 vs $2.42 Est; Affirms FY2026 Sales Guidance of $2.111B-$2.132B vs $2.139B Est Qiagen (NYSE:QGEN) FY2026 expected to be more than $2.43 vs $2.42 Est. affirms FY2026 sales outlook from $2.111 billion-$2.132 billion to $2.111 billion-$2.132 billion vs $2.139 billion estimate.
- benzinga.com Qiagen Q2 Adj. EPS $0.62 Beats $0.60 Estimate, Sales $535.000M Beat $527.484M Estimate Qiagen (NYSE:QGEN) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0.60 by 3.33 percent. This is a 8.77 percent increase over earnings of $0.57 per share…
- benzinga.com Qiagen Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak; Says Qiagen’s FDA-Cleared QIAstat-Dx Gastrointestinal Panel 2 Can Detect Cyclospora Infections In About An Hour As Part Of A 16-Target Gastrointestinal Pathogens Menu More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwideQIAGEN’s FDA-cleared QIAstat-Dx…
benzinga.com Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover Private equity giants circle Qiagen (QGEN) with potential bids of $50/share. Get the details on the molecular diagnostics buyout.
benzinga.com Morgan Stanley Upgrades Qiagen to Overweight, Raises Price Target to $42 Morgan Stanley analyst Steve Beuchaw upgrades Qiagen (NYSE:QGEN) from Equal-Weight to Overweight and raises the price target from $40 to $42.- benzinga.com QIAGEN Expands QIAcuity Digital PCR Portfolio Into Gene Expression, Cell And Gene Therapy And Automated Workflows To Drive Broader Adoption Across Life Sciences Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areasExpanded Cell and Gene Therapy…
- benzinga.com Qiagen Announces That QIAGEN Digital Insights Bioinformatics Business And Its Curated Knowledge Bases And Bioinformatics Expertise Will Be Integrating NVIDIA Accelerated Computing And The NVIDIA Bionemo Platform To Help Researchers Use AI More Effectively In Drug Discovery QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insights bioinformatics business and its curated knowledge…
- benzinga.com Stifel Maintains Hold on Qiagen, Lowers Price Target to $36 Stifel analyst Daniel Arias maintains Qiagen (NYSE:QGEN) with a Hold and lowers the price target from $50 to $36.
- benzinga.com QIAGEN's 2026 AGM To Feature 40% Dividend Increase To $0.35/Share, $200M Buyback And Co-Founder Colpan As Honorary Chairman Co-founder and former CEO Dr. Metin Colpan to become Honorary Chairman of the Supervisory Board after deciding not to stand for re-electionRobert McMahon nominated for election to Supervisory Board…
- benzinga.com TD Cowen Maintains Hold on Qiagen, Lowers Price Target to $40 TD Cowen analyst Dan Brennan maintains Qiagen (NYSE:QGEN) with a Hold and lowers the price target from $46 to $40.
- benzinga.com QIAGEN Plans To Advance QuantiFERON Latent TB Test With Automated Sample To Insight Workflow And Separate AI-Enabled Risk Stratification Tool For TB Progression Ambition to support high-throughput laboratories in efficiently scaling latent tuberculosis (TB) screening as testing volumes continue to growFully automated workflow targeted for late 2027 launch…
- benzinga.com UPDATE: Qiagen FY2026 expected to be more than $2.43 vs $2.51 Est; Affirms FY2026 Sales Guidance of $2.111B-$2.132B vs $2.183B Est Qiagen (NYSE:QGEN) FY2026 expected to be more than $2.43 vs $2.51 Est. affirms FY2026 sales outlook from $2.111 billion-$2.132 billion to $2.111 billion-$2.132 billion vs $2.183 billion estimate.
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com JP Morgan Maintains Overweight on Qiagen, Lowers Price Target to $45 JP Morgan analyst Casey Woodring maintains Qiagen (NYSE:QGEN) with a Overweight and lowers the price target from $60 to $45.
- benzinga.com Citigroup Maintains Neutral on Qiagen, Lowers Price Target to $38 Citigroup analyst Patrick Donnelly maintains Qiagen (NYSE:QGEN) with a Neutral and lowers the price target from $55 to $38.
benzinga.com Barclays Maintains Equal-Weight on Qiagen, Lowers Price Target to $38 Barclays analyst Luke Sergott maintains Qiagen (NYSE:QGEN) with a Equal-Weight and lowers the price target from $44 to $38.
benzinga.com This Crane Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Analysts upgraded Qiagen, Armstrong World, T-Mobile, Crane Co, and Centene Corp stocks, with price target changes. See their ratings and views.
benzinga.com Starbucks To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts change outlook & ratings for QGEN, AWI, CR, ATEN, PLUG, SBUX, CECO, CNC. Price targets raised for QGEN, AWI, CR, ATEN, PLUG, SBUX, CECO.- benzinga.com Baird Upgrades Qiagen to Outperform, Lowers Price Target to $43 Baird analyst Catherine Schulte upgrades Qiagen (NYSE:QGEN) from Neutral to Outperform and lowers the price target from $53 to $43.
benzinga.com Stock Market Today: S&P 500 Drops Amid Tech Sell-Off, Oil Climbs To $100 On Hormuz Drama Tech stocks slide as OpenAI's user growth miss reignites AI capex skepticism, while oil rallies above $99 and the Fed's two-day meeting kicks off.- benzinga.com Barclays Downgrades Qiagen to Equal-Weight, Announces $44 Price Target Barclays analyst Luke Sergott downgrades Qiagen (NYSE:QGEN) from Overweight to Equal-Weight and announces $44 price target.
- benzinga.com QIAGEN Publishes New Clinical, Health Economic Data On Use Of Its QuantiFERON-TB Gold Plus Blood Test To Trace Tuberculosis Infection QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced newly published clinical and health economic data supporting the use of its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for…
benzinga.com This Nio Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - benzinga.com Deutsche Bank Upgrades Qiagen to Buy, Maintains Price Target to $54 Deutsche Bank analyst Jan Koch upgrades Qiagen (NYSE:QGEN) from Hold to Buy and maintains the price target from $54 to $54.
- benzinga.com Qiagen Obtains U.S. FDA Clearance For Gastrointestinal Panels On Fully Automated QIAstat-Dx Rise Syndromic Testing System QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced that the U.S. Food and Drug Administration (FDA) has cleared the use of all QIAstat-Dx® Gastrointestinal (GI) Panels on the…
benzinga.com HIVE Digital Technologies, First Majestic Silver, Iamgold And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - benzinga.com JP Morgan Maintains Overweight on Qiagen, Raises Price Target to $60 JP Morgan analyst Casey Woodring maintains Qiagen (NYSE:QGEN) with a Overweight and raises the price target from $55 to $60.
- benzinga.com Stifel Maintains Hold on Qiagen, Raises Price Target to $50 Stifel analyst Daniel Arias maintains Qiagen (NYSE:QGEN) with a Hold and raises the price target from $45 to $50.
- benzinga.com Qiagen FY2026 expected to be more than $2.50 vs $2.66 Est; FY2026 Revenue expected to be more than $2.194B vs $2.214B Est Qiagen (NYSE:QGEN) FY2026 expected to be more than $2.50 vs $2.66 Est. FY2026 Revenue expected to be more than $2.194B vs $2.214B Est